Basal Cell Carcinoma: To Targeted Therapy and Beyond—High-Risk Basal Cell Carcinoma: Navigating Treatment and Complications

Activity Overview

Treatment decisions in basal cell carcinoma (BCC) are driven by estimated risk for recurrence. Although surgery is the treatment of choice for the majority of high-risk BCC, some large, deep, aggressive, or recurrent tumors can be classified as locally advanced and are best treated with systemic therapy. This Infographic activity provides detailed education on identifying high-risk BCC, the rationale for Mohs surgery, and appropriate use of local therapies. The role and place of systemic therapy is also defined, with an emphasis on the efficacy and limitations of Hedgehog pathway inhibitors (HPI) and the recent emergence of immunotherapy on the treatment landscape.

0.25 CE Credit(s)
Expires: June 3, 2022

Target Audience

This activity is designed to meet the educational needs of dermatology and oncology physicians who diagnose and manage patients with basal cell carcinoma (BCC).

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Assess current treatment options for the management of high-risk basal cell carcinoma (BCC)

 

Activity Faculty

Hamid, Omid

Omid Hamid, MD

Chief, Translational Research and Immunotherapy
Director, Melanoma Center and Phase I Immuno-Oncology Program
The Angeles Clinic and Research Institute
Los Angeles, CA